85 articles - From Friday Mar 28 2025 to Friday Apr 04 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Endoscopy |
|---|
Use of computer-assisted detection (CADe) colonoscopy in colorectal cancer screening and surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. This is due to the potential benefits, although limited, of reduction in colorectal cancer incidence and mortality. This recommendation is weak, because the evidence is limited with considerable uncertainty of the evidence estimates, the absolute benefits for colorectal cancer incidence and mortality are small, and there is a patient burden associated with CADe (more polyp overdiagnosis and more colonoscopy surveillance). |
| Gut |
British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis. The aim of this guideline is to review and summarise the current evidence, in order to inform and guide diagnosis and management of patients with AIH and its variant syndromes. The main focus is on AIH in adults, but the guidelines should also be relevant to older children and adolescents. |
meta-analyses and systematic reviews
| Am J Gastroenterol |
|---|
Colonoscopy-related adverse events in the 21st century: an updated systematic review and meta-analysis. This comprehensive meta-analysis provides valuable insights into the global incidence of colonoscopy-related AEs and underscores the imperative need for continuous efforts to enhance the safety of this procedure. |
Overall and Cause-Specific Mortality in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis of Population-Based Studies. BE patients exhibit a higher all-cause mortality, driven in part by risk of EC mortality. A personalized approach to surveillance, mitigating risk of EC while recognizing the broader mortality risks, is warranted. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Afamin and Apolipoprotein F Associated With Liver Steatosis From People Living With HIV: A Discovery Study. These findings suggest that the identified proteins could serve as promising biomarkers of LS in PLWH, paving the way for further investigations into the roles of these proteins in LS development in this unique population. |
Association of High-Sensitivity Troponins in Metabolic Dysfunction-Associated Steatotic Liver Disease With All-Cause and Cause-Specific Mortality. Screening hs-troponin T or I in individuals with MASLD can identify at-risk subpopulations within this group that have a higher risk for future all-cause mortality, predominantly due to cardiovascular disease-related mortality in the population without cardiovascular disease. |
Limitations of Faecal Calprotectin in Detecting Histological Changes and Persistent Villous Atrophy in Patients With Coeliac Disease on a Gluten-Free Diet. Although significant histological lesions (Marsh II-III) decreased from 24% to 10%, faecal calprotectin levels fluctuated without correlation to anti-transglutaminase, adherence or histological remission, and did not differentiate between lesion grades. Our findings underscore faecal calprotectin's unreliability in monitoring mucosal healing in adults with coeliac disease, highlighting the urgent need for alternative biomarkers. |
| Am J Gastroenterol |
ALADDIN: A Machine Learning Approach to Enhance the Prediction of Significant Fibrosis or Higher in MASLD. Along with the SAFE model developed to target significant fibrosis or higher, ALADDIN-F2-VCTE ( uniquely supports a refined non-invasive approach to patient selection for resmetirom without the need for liver biopsy. Additionally, ALADDIN-F2-Lab ( offers an effective alternative when VCTE is unavailable. |
Association of Components of Metabolic Syndrome and the Progression of Nonalcoholic Fatty Liver Disease. In the cohort of NAFLD patients, MetS was associated with greater histological severity at baseline but was not a risk factor for disease progression or regression. Impaired glucose/diabetes was associated with a higher rate and hypertension with a lower rate of fibrosis progression. |
Association of Race and Ethnicity with Healthcare Utilization for Inflammatory Bowel Disease in the United States: A Retrospective Cohort Study. Healthcare utilization for long-term management of inflammatory bowel disease is lower in historically marginalized racial and ethnic groups compared to White Americans. Further research is needed to identify and address modifiable patient, clinician, and healthcare system barriers to achieve health equity in the management of inflammatory bowel disease. |
Characteristics of post-polypectomy colorectal cancer events and deaths. Most PPCRC events and deaths were diagnosed before the next recommended exam, largely due to procedural factors, underscoring the need to optimize quality of baseline colonoscopy and polypectomy. Many PPCRCs were diagnosed after recommended exam, suggesting the need to improve patient adherence to recommended surveillance intervals. |
Gastric (Foveolar) Dysplasia in Barrett's Esophagus: A Clinical, Molecular and Long-Term Outcome Study. Gastric type dysplasia is common in BE. Our study suggests that this type of dysplasia may represent a more aggressive form of neoplastic precursor than conventional intestinal type dysplasia. |
Incidence and survival of colorectal cancer in the United Kingdom from 2000-2021: a population-based cohort study. Although the overall incidence in the population has plateaued, a worrying increasing trend of early-onset CRC was observed. Moreover, the slight improvement in overall survival suggests that significant progress is still needed. These findings highlight the urgent need for continued research and resource allocation to improve the diagnosis and management of colorectal cancer. |
Liver Cleansing Imposters: An Analysis Of Popular Online Liver Supplements. This study reveals a thriving market for liver supplements despite limited scientific evidence supporting their efficacy. The prevalence of bold health claims, high consumer satisfaction, and significant sales highlight the need for more rigorous evaluation and regulation of these products. Healthcare providers should be aware of these trends to better counsel patients on evidence-based approaches to liver health. |
Loss of response to off-label swallowed topical corticosteroids in eosinophilic esophagitis can be overcome by a switch to an esophageal-targeted budesonide formulation. Most patients non-responding to olSTC are not true corticosteroid-refractory but respond to an esophageal-targeted budesonide formulation. Age below 30 years, longer treatment duration and low adherence are associated with olSTC-failure. |
Raising the age for starting colonoscopy to 35 years for individuals with path_MSH6 carriers may lead to missed opportunities for detecting advanced neoplasia in a notable percentage of carriers. Our findings suggest that the recommendation to raise the age for initiating colonoscopy to 35 years for path_MSH6 carriers merits careful consideration, as there is a possibility that AN may not be detected. Given the limited size of our study and the potential for ascertainment bias, we encourage further research to explore and validate our findings. |
Safety and Efficacy of Endoscopic Retrograde Appendicitis Therapy for pediatric patients: A Single-Center Retrospective Study in Chinese Children. ERAT appears to be a safe and effective alternative approach to treat appendicitis in pediatric patients, especially for obstructive appendicitis with appendicolith. |
| Endoscopy |
Peroral endoscopic myotomy for symptomatic blown-out myotomy following previous myotomy for achalasia. Clinical success was equivalent between the two groups at the 2-year follow-up (85.7% vs 92.3%; = 0.16). Based on this study, POEM could be considered as an effective treatment option for patients with symptomatic BOM. |
Proton pump inhibitors are associated with occlusion of lumen-apposing metal stents and higher frequency of endoscopic necrosectomies - A European-wide multicenter cohort study. Intake of PPIs upon LAMS placement is associated with a higher LAMS occlusion and necrosectomy rate. |
| Gastroenterology |
AI-Enabled Clinical Trials in IBD: Automating and Enhancing Disease Assessment and Study Management. Large language models and generative AI are automating the collection of high-quality data from electronic records and improving our ability to predict patient outcomes. This narrative review will focus on AI tools available today, their expected implementation, and future-facing opportunities for AI to reimagine IBD clinical trials. |
Active inflammatory bowel disease on intestinal ultrasound during pregnancy is associated with an increased risk of adverse pregnancy and neonatal outcomes independent of clinical and biochemical disease activity. Active IBD on IUS in pregnancy is associated with an increased risk of adverse pregnancy outcomes, independent of clinical activity and FCP. Use of IUS monitoring antenatally should be considered to guide therapeutic decision making. |
Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. These findings emphasize the critical interplay between extrinsic matrix stiffness and intrinsic IGF2BP2-regulated sphingomyelin synthesis, identifying a promising target for immunotherapeutic strategies in PDAC. |
| Gastrointest Endosc |
| Gut |
Combining faecal haemoglobin, iron deficiency anaemia status and age can improve colorectal cancer risk prediction in patients attending primary care with bowel symptoms: a retrospective observational study. Combining f-Hb, patient age and IDA status improves CRC risk prediction, identifies a low-risk group with f-Hb<20 µg Hb/g and no IDA and could inform revised referral guidance. |
Stressed hepatocyte sustains alcohol-associated hepatitis progression by producing leukocyte cell-derived chemotaxin 2. Our studies identified a novel vicious cycle between neutrophils and hepatocytes through the LECT2-PHB2 interaction, presenting a promising therapeutic intervention by targeting LECT2 to mitigate AH in patients. |
Tumour-intrinsic alterations and stromal matrix remodelling promote Wnt-niche independence during diffuse-type gastric cancer progression. Our findings demonstrate that tumour cell-derived ligand expression and extracellular matrix remodelling sustain Wnt signalling during DGC progression. These complementary mechanisms promote niche independence enabling expansion of undifferentiated DGC cells needed for the development of advanced tumours. |
| Hepatology |
Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation. In this real-world analysis, immunotherapy was associated with improved OS compared to lenvatinib in advanced HCC, with consistent benefit across most subgroups. These findings support the use of immunotherapy as a first-line treatment for advanced HCC. |
Epidemiological and economical burden of cholestatic liver disease. An accurate understanding of the epidemiology and burden of disease on both the individual and society of cholestatic diseases is of great importance. This review aims at providing a comprehensive overview of the current literature on the epidemiology, health related quality of life, and economical burden of PSC, PBC, and IgG4-C. |
Getting to HBV Cure - will new biomarkers help? In this review, the serological, virological and immunological biomarkers are described with a focus on how they can be used to guide development of HBV cure strategies. New terminology is proposed for clinical endpoints, including Sustained Control to replace the concept of partial cure and Resolved Chronic Infection to replace Functional Cure, reserving the term Cure for clearance or silencing of al cccDNA and integrated HBV DNA. |
| J Hepatol |
Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden. MASLD was strongly associated with liver- and HCC-related mortality, but the absolute risks of death were highest for non-HCC cancer and cardiovascular disease. Mortality was increased for nearly al causes in patients with MASLD, suggesting that earlier multidisciplinary care is needed to reduce excess mortality. Impact and implications Previous studies on mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) were either small, restricted to liver-related mortality, relying on liver biopsy to identify patients and thus inducing selection bias, or mainly using data from old cohorts. In a nationwide cohort study of al patients diagnosed with MASLD in inpatient or specialized outpatient care in Sweden between 2002 and 2020, we found a nearly doubled all-cause mortality rate and higher mortality than the general population from a wide range of causes, indicating that earlier multidisciplinary care may be needed to reduce premature mortality in patients with MASLD. The absolute risk estimates of death in our study may be useful for clinicians and policymakers to inform patients about their prognosis and potentially implement clinical or public health strategies to reduce premature mortality. |
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study. HRQoL was maintained after adding pembrolizumab to gemcitabine and cisplatin, further supporting this regimen as first-line treatment for advanced BTC. Impact and implications Biliary tract cancer (BTC) is often diagnosed at late stages because most patients do not present with disease-specific symptoms. Compared with the general population, patients with advanced BTC report worse physical, emotional, and functional well-being. In KEYNOTE-966, adding the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab to gemcitabine and cisplatin as first-line therapy for participants with advanced BTC produced a statistically significant and clinically meaningful improvement in overall survival. The prespecified patient-reported outcomes results from KEYNOTE-966 presented herein demonstrated that health-related quality of life was maintained after adding pembrolizumab to gemcitabine and cisplatin, further supporting this regimen as first-line treatment for advanced BTC. Clinical trial registration |
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials. The addition of nal-IRI to 5-FU/LV significantly improved PFS and ORR, supporting its potential as subsequent-line therapy. Differences in safety profiles underscore the relevance of ethnicity for nal-IRI in patients with BTC. Impact and implications Current standard of care for second-line therapy in patients with advanced biliary tract cancer (BTC) is FOLFOX. This study provides robust evidence supporting the potential role of additional liposomal irinotecan (nal-IRI) to fluorouracil and leucovorin (5-FU/LV) as a subsequent therapy for patients with BTC who have progressed on gemcitabine-based regimens. The findings demonstrate significant improvements in progression-free survival and overall response rates, emphasizing its potential to address the limited treatment options in this patient population. Furthermore, the study underscores the necessity of considering ethnic differences in adverse event profiles to optimize treatment administration and patient outcomes. Clinical trial registration |
eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma. Targeting the eIF3f-ACSL4-FAB axis could decelerate HCC malignancy and enhance anti-programmed cell death-1 efficacy, suggesting that eIF3f is a potential target for precision therapy in HCC. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
Review Article: Individualised Management of Reflux-Like Symptoms-Strategies Beyond Acid Suppression. A paradigm shift in reflux-like symptom management is required such that acid suppression is viewed as one of several interventions that can be utilised as part of a phenotype-driven, individualised approach to care that acknowledges the multiple contributors to symptom burden. |
| Clin Gastroenterol Hepatol |
Burden of Non-malignant Liver and Pancreatic Diseases in the United States Population: Rates and Trends. The burden of non-malignant liver and pancreatic diseases in the United States is substantial. The rise in liver disease mortality rates following the reversal of a previous downward trend is particularly concerning. Hence ongoing surveillance of liver disease and pancreatitis prevalence may better inform research programs. |
| J Hepatol |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endoscopy |
| Gastroenterology |
| Gut |
| Hepatology |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Gastroenterology |
| Gut |
| J Hepatol |